pharmaphorum2d
AbbVie launches pump-based Parkinson’s drug in EU
AbbVie has launched its Produodopa therapy for Parkinson’s disease onto the market in the EU, becoming the first and only 24-hour levodopa-based subcutaneous infusion therapy for the ...
GlobalData on MSN3mon
FDA approves AbbVie’s VYALEV for advanced Parkinson’s treatment
VYALEV, also known as PRODUODOPA, is the first and only subcutaneous ... 2,400mg foslevodopa per 10ml solution dose. AbbVie ...
pharmaphorum11mon
AbbVie’s 24-hour Parkinson’s therapy to roll out on NHS
Around 1,000 people with Parkinson’s disease will be able to access treatment with AbbVie’s Produodopa, the first therapy that can be delivered by a 24-hour subcutaneous infusion pump ...
Hosted on MSN3mon
AbbVie Secures FDA Approval for Parkinson's Disease Drug Vyalev
AbbVie ABBV announced that the FDA has approved ... where it is marketed under the trade name Produodopa. The drug’s coverage for Medicare patients is expected in the second half of next year.
Yahoo Finance7d
AbbVie Takes $3.5B Impairment Charge for Failed Schizophrenia Drug
AbbVie said it would take a $3.5 billion dollar impairment charge related to the failure of a drug it acquired in its purchase of Cerevel Therapeutics. The biotech company reported in November ...